In most cases, Anthem does not cover Zepbound for weight loss. Elevance Health, which operates the Anthem health plans, has stated that it does not cover GLP-1 drugs prescribed for weight loss except where state law requires it, and across most Anthem plan types weight-loss medications are either explicitly excluded or buried behind strict prior authorization.1Becker’s Payer. Elevance Health Does Not Cover Weight Loss Drugs in Most Cases, CFO Says Coverage still varies by plan type, state, and the medical reason on the prescription, and a few narrow pathways do exist.
How Coverage Breaks Down by Plan Type
Employer-Sponsored Plans
Most Anthem employer-sponsored plans do not cover weight-loss medications. Many fully insured large group plans added explicit exclusions for weight-loss drugs effective January 1, 2025.2Word & Brown. Weight Loss Drugs (GLP-1) Coverage Self-funded employers set their own benefits and some choose to include coverage, so the real answer for a given worker depends on what the employer bought, not on Anthem alone. Where coverage does exist, prior authorization is required, and plans often impose step therapy such as a documented diet and exercise program or a trial of older, cheaper weight-loss medications before approving Zepbound.3PEAK Wellness VA. Anthem Coverage
Anthem uses several different formulary lists that vary by employer and state. You generally cannot tell which one applies to you from the public website. Log into your member portal or call the pharmacy services number on your ID card to find out whether Zepbound appears on your plan’s drug list at all.4Anthem. Drug List Formulary
Individual and ACA Marketplace Plans
Coverage on Anthem’s individual marketplace plans varies by state and metal tier. When Zepbound is covered, it typically sits on a non-preferred tier with higher cost-sharing and strict prior authorization.5FindHonestCare. Zepbound Insurance – Anthem Blue Cross In California, all GLP-1 drugs were classified as Tier 4 specialty drugs and treated as non-formulary as of January 2025, with claims processed as an exclusion.2Word & Brown. Weight Loss Drugs (GLP-1) Coverage
Medicaid Managed Care
Anthem administers Medicaid managed care plans in several states, and the state’s Medicaid agency sets most of the rules. Two states show how far apart the outcomes can be.
In California, Medi-Cal removed Zepbound, Wegovy, and Saxenda from its Contract Drugs List for weight-loss indications effective January 1, 2026. Claims for these drugs now receive an automatic denial regardless of the indication listed. The only exception on the weight-loss side is that prior authorization requests for Zepbound will be considered when the drug is prescribed for obstructive sleep apnea. For members under 21, weight-loss prescriptions can still be reviewed for medical necessity under the federal EPSDT benefit.6Anthem Providers. GLP-1 Coverage Update – California
In Virginia, Anthem HealthKeepers Plus does cover Zepbound for weight loss under strict criteria. The patient must have a BMI above 40, or above 37 with conditions like diabetes or hypertension, and must have tried and failed a non-GLP-1 weight-loss drug over a six-month period. The prescriber must attest that the patient’s obesity is “disabling and life threatening.” Initial authorizations last six months, and renewals require at least a 5% reduction in body weight.7Anthem Providers. Prior Authorization Form – Weight-Loss Management (Virginia)
If you are on an Anthem Medicaid plan, check with your state program or call the number on your member ID card before assuming anything.
Medicare Advantage
Federal law has long excluded weight-loss drugs from Medicare Part D coverage, and Anthem Medicare Advantage plans follow that restriction. Zepbound prescribed for weight loss is not covered through the standard Part D benefit.8KFF. Medicaid Coverage of and Spending on GLP-1s A new federal demonstration opened a separate door in 2026, discussed below.
The Sleep Apnea Pathway
Zepbound has two FDA approvals. It was approved for chronic weight management in November 2023, and again in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity.9U.S. Food and Drug Administration. FDA Approves First Medication for Obstructive Sleep Apnea10Eli Lilly and Company. FDA Approves Zepbound (Tirzepatide) First and Only Prescription That second approval matters, because many Anthem plans write their exclusion as “drugs used for weight loss” rather than as a ban on tirzepatide. A prescription written for sleep apnea can sometimes clear a plan that would reject the same drug for weight management.
Anthem’s Virginia Medicaid plan has a separate prior authorization form for GLP-1 medications prescribed for OSA. Clinical criteria require the patient to be at least 18, have a BMI of 30 or higher, and have moderate-to-severe OSA confirmed by a sleep study showing at least 15 breathing interruptions per hour. The patient must be currently using CPAP therapy or have documented that CPAP failed or could not be tolerated. If approved, the initial authorization lasts six months, with 12-month renewals available upon demonstrated improvement.11Anthem Providers. GLP-1 RAs for Obstructive Sleep Apnea Prior Authorization Form California’s Medi-Cal carved out a similar exception while rejecting weight-loss requests outright.6Anthem Providers. GLP-1 Coverage Update – California
If you have both obesity and sleep apnea, raise the OSA indication with your doctor. On an Anthem plan that excludes weight-loss drugs, this is often the most realistic route to coverage.
The Medicare GLP-1 Bridge Program
From July 1, 2026 through at least December 31, 2027, the federal Medicare GLP-1 Bridge Program offers a new way for Medicare beneficiaries to access Zepbound for weight loss. The program runs entirely outside standard Part D benefits, so it applies regardless of whether your Anthem Medicare Advantage plan lists the drug on its formulary.12Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge
To qualify, you must be enrolled in a Part D plan or a Medicare Advantage plan with drug coverage, and meet one of these clinical thresholds:
- BMI of 35 or higher
- BMI of 30 or higher with heart failure, uncontrolled hypertension, or chronic kidney disease
- BMI of 27 or higher with pre-diabetes, history of heart attack, stroke, or peripheral artery disease
Your doctor submits the prior authorization and prescription to the program’s central processor (Humana manages it on behalf of CMS), not to your Anthem plan. You pay a flat $50 copay per monthly supply. That copay does not count toward Part D deductibles or out-of-pocket limits.12Centers for Medicare & Medicaid Services. Medicare GLP-1 Bridge13Medicare Rights Center. GLP-1 Weight Loss Drug Demonstration Begins July 2026 A broader program that would have extended coverage into regular Part D plans was delayed indefinitely after too few drug plans volunteered.14American Hospital Association. CMS Delays Part D Portion of BALANCE Model Expansion of GLP-1 Access The Bridge Program is the only federal pathway for Medicare enrollees seeking Zepbound for weight loss.
What Zepbound Costs Without Anthem Coverage
If your plan refuses to cover Zepbound, the list price runs from about $499 to over $1,086 per fill depending on the dose. Eli Lilly offers a savings card that can bring the cost down to $25 per month for patients whose commercial insurance covers the drug, or to $449 to $499 per month at maintenance doses for people paying out of pocket.15Eli Lilly and Company. Zepbound Pricing Information16Eli Lilly and Company. Zepbound Savings Patients on Medicare or Medicaid are not eligible for the manufacturer savings card.
If Your Zepbound Claim Is Denied
The first step after any denial is to get a written explanation of the specific reason. Common denial reasons include a plan exclusion for weight-loss drugs, failure to meet prior authorization criteria, or an incorrect diagnosis code on the claim. The right next move depends on which one applies.
If your plan contains an outright exclusion for weight-loss medications, a standard prior authorization appeal is unlikely to succeed. The more productive move is to look at the sleep apnea pathway if you qualify, or to ask your prescriber whether another covered indication fits your diagnosis.
When the denial comes from prior authorization criteria rather than a blanket exclusion, you and your doctor can appeal by submitting additional documentation. That typically means medical records showing your BMI and weight-related conditions, evidence of prior diet and exercise efforts, and a letter from the prescriber explaining why the medication is medically necessary.17Obesity Action Coalition. Appealing a Denial For employer plans governed by ERISA, patients who exhaust internal appeals can request an external review. Some states offer independent external review processes for fully insured plans as well.
State Mandates May Change the Answer
The coverage picture is shifting. North Dakota became the first state to mandate insurance coverage for GLP-1 medications by updating its essential health benefit benchmark plan, effective January 2025.18Pharmacy Times. States Push Forward on Insurance Mandates for GLP-1 and Obesity Treatments At least 13 other states have introduced bills that would require insurers to cover anti-obesity medications, including California, Connecticut, Iowa, Maine, Washington, and West Virginia.19LexisNexis. States Consider Requiring Insurers to Cover Weight Loss Drugs
If a mandate passes in a state where Anthem operates, the company would be required to cover Zepbound on fully insured plans in that state regardless of its current policy. Elevance’s CFO has acknowledged that the company covers GLP-1s for weight loss where state law requires it.1Becker’s Payer. Elevance Health Does Not Cover Weight Loss Drugs in Most Cases, CFO Says Self-funded employer plans, which fall under federal ERISA rules rather than state insurance mandates, would generally remain unaffected.